STEP 1 Trial Explained: Semaglutide 2.4 mg for Obesity in 2 Minutes
About this episode
This episode explains the STEP 1 trial and its findings on semaglutide for obesity treatment.
Can once-weekly semaglutide produce meaningful weight loss in adults with obesity? In this 2-minute evidence brief, we break down the STEP 1 trial, a randomized double-blind clinical trial published in the New England Journal of Medicine in 2021. The study tested semaglutide 2.4 mg once weekly versus placebo, both with lifestyle intervention, in adults with overweight or obesity but without diabetes. Covered in this video: Why the STEP 1 trial was done How the trial was conducted Main weight loss results Safety and gastrointestinal side effects Key clinical takeaway Main result: average body weight decreased by 14.9% with semaglutide versus 2.4% with placebo over 68 weeks. Citation: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. PMID: 33567185 DOI: 10.1056/NEJMoa2032183 This video is for medical education only and does not replace clinical judgment or individual medical advice. #Semaglutide #STEP1Trial #ObesityMedicine #GLP1 #MedicalEducation semaglutide, STEP 1 trial, semaglutide obesity, semaglutide weight loss, Wegovy, GLP-1 receptor agonist, obesity treatment, obesity medicine, clinical trial explained…
More episodes of Hormone Insight
- Jun 27, 2026: This Week in Diabetes & Endocrinology -- The triple agonist arrives, and the bar moves
- An Oral GLP-1 That Works: ATTAIN-2 and the 2026 ADA Standards | This Week in Diabetes & Endocrinology
Explore listener stats, chart rankings, contacts and more on the Hormone Insight podcast page.